USFDA finds significant violations of CGMP at Cadila's Moraiya plant

In a warning letter issued to the company's Chairman Pankaj R Patel, the US Food and Drug Administration pointed out various deficiencies at the plant, including inadequate cleaning procedure for non-dedicated equipment.
"Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and/or sterilise equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety identity, strength, quality, or purity of the drug product beyond the official or other established requirements," the US health regulator said in the letter.
The USFDA officials, who inspected the plant from April 22 to May 3, 2019, said the significant equipment flaws and cleaning deficiencies resulted in cross-contamination between the drug products.
The US health regulator also pointed towards the failure of the company to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications.The US health regulator did not approve of the resolutions brought in by the drug maker at the facility, terming the steps as inadequate.
"Your firm failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes," it further noted.
Besides, the company failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas, it added.
"In previous warning letters, FDA cited similar CGMP violations. You proposed specific remediation for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate," the USFDA said.
Until all corrections have been completed and FDA has confirmed corrections of the violations and the firm's compliance with CGMP, FDA may withhold approval of any new applications or supplements, the USFDA said.
In addition, the company's failure to correct these violations may result in FDA continuing to refuse admission of articles manufactured at the plant into the US, it added. The FDA issued the letter on October 29, and has given the company 15 days to respond. MSS BAL(This story has not been edited by Business Insider and is auto-generated from a syndicated feed we subscribe to.)

Rudy Giuliani reportedly needed a translation app on his phone for Russian documents. He was without his associates who were arrested in October.

Uber's co-founder and former CEO Travis Kalanick sold off close to $166 million shares over the past three days, continuing to offload his stake in the ride-sharing giant

13 fascinating animal species discovered in the last decade, from the 'Wakanda' fish to the world's tiniest frog

These jobs may disappear in the coming years with the advancement in technology

If we do decide to inhabit Mars, what would happen?
What is citizenship bill and how does it affect religious freedom in India?
India is slowing down so fast that even experts can’t keep up
Meet the 33-year-old Chennai techie who spotted Vikram Lander on Moon’s surface and alerted NASA
Raghuram Rajan's warning about Mudra loans last year may be coming true
Microsoft’s four-day work week idea will be good for Indians— but there is a lot to be fixed before that
Dues, death and an investigation — all that went wrong with OYO hotels in the last 6 months
Three wise men who exited Vodafone India just in time to make millions
SAIF Partners invested in Swiggy when they just had a landing page – today they are going after more seed stage startups, here’s why
SIGN IN WITH
FacebookGoogleEmail